Avelumab 10 mg/kg

DRUG2 trials

Sponsors

Merck KGaA, Darmstadt, Germany, Samsung Medical Center

Conditions

Solid TumorsUpper Tract Urothelial Carcinoma

Phase 1

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)

CompletedNCT01943461

Merck KGaA, Darmstadt, GermanySolid Tumors

Start: 2013-09-02End: 2019-09-25Updated: 2020-09-30

Phase 2

Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC

RecruitingNCT07225374

Samsung Medical CenterUpper Tract Urothelial Carcinoma

Start: 2025-09-16End: 2029-07-02Target: 48Updated: 2025-11-06

Related Papers

Changing Body Weight–Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma

Clinical Pharmacology & Therapeutics2019-09-2543 citations

Avelumab (anti–PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from the phase Ib JAVELIN solid tumour JPN trial

Annals of Oncology2018-10-012 citations

Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric or gastroesophageal junction cancer.

Journal of Clinical Oncology2016-02-0113 citations

A phase I dose expansion trial of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric cancer.

Journal of Clinical Oncology2015-05-2018 citations

Phase I, open-label, multi-ascending dose trial of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.

Journal of Clinical Oncology2015-05-2012 citations